Dr. Thomas Williams at Breast Care Specialists of Carolina in Mooresville, North Carolina is an advocate for treating the whole person using an individualized and personalized approach. She is committed to providing women with treatment options that suit their needs physically, emotionally, and spiritually, while never compromising the quality of care provided. This approach includes utilizing cutting-edge diagnostics; Dr. Thomas Williams is the only breast surgeon in the area implementing 150 gene testing to inform pre-operative treatment planning. Dr. Thomas Williams is dedicated to providing both proper and timely breast cancer treatment which leads most women to go on and pursue rich and fulfilling lives.


The MammaPrint® and BluePrint® genomic tests are used to uncover a breast tumor’s unique traits to help form a targeted treatment plan specific to each patient’s individual needs. MammaPrint® is used to determine the risk that a patient’s cancer will return. BluePrint® is used to determine which of the tumor’s genes are dictating the cancer’s behavior. When used together MammaPrint ® and BluePrint® uncover more tumor biology affording us a clearer picture for a more personalized treatment strategy.

Contact Breast Care Specialists of Carolina today to discuss your diagnosis and treatment options.


The DCISionRT test combines the latest innovations in molecular biology with artificial intelligence and machine learning to deliver the most advanced DCIS test available. DCISionRT is the first biological risk signature developed specifically for DCIS and the only test that predicts whether or not radiation therapy would be beneficial. Based on the biology of your DCIS, the DCISionRT test provides you and your physician the information needed to make a decision whether surgery alone or surgery with radiation therapy is appropriate.


Breast Cancer Index (BCI) is a test that provides information to help women diagnosed with early-stage, hormone receptor-positive (HR+) breast cancer, and their oncologists make personalized decisions about extending anti-estrogen (also called hormonal or endocrine) therapy beyond 5 years.

Breast Cancer Index is a test that looks at your initial tumor sample to provide two pieces of information:

Whether an additional 5 years of anti-estrogen therapy is likely to help reduce your risk of the cancer returning (recurrence) as metastatic disease.
Your individual risk of metastatic recurrence between 5 and 10 years after initial diagnosis, which is presented as a percentage risk [e.g., 3.2% or 7.5%].

Join us for Breast Cancer After Hours on the last Tuesday of every month. Call to learn more!